Aligos Therapeutics (ALGS) AI Stock Analysis

• Market Cap: $46.84M
• Dividend Yield: N/A
• Average Volume (3M): 86.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: -55.88%
• EPS Growth: 6.14%
• Country: US
• Employees: 70
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.91
• Shares Outstanding: 5,387,807
• 10 Day Avg. Volume: 122,947
• 30 Day Avg. Volume: 86,969
• PEG Ratio: 0.04
• Price to Book (P/B): 1.72
• Price to Sales (P/S): 42.14
• P/FCF Ratio: -1.11
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 15.71
• Enterprise Value/Gross Profit: 20.56
• Enterprise Value/Ebitda: -0.40
• 1Y Price Target: $35.00
• Price Target Upside: 362.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -6.65
• Revenue Forecast (FY): $1.70M

• Rating: 42 Neutral
• Price Target: $6.50 ▼(-14.13% Downside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is mainly held down by very weak financial performance (zero revenue in 2025, persistent losses, and heavy cash burn) and a bearish technical setup (below key moving averages with negative MACD). Valuation offers limited support due to ongoing losses and no dividend, while the leadership/accounting appointment is a modest positive but not enough to offset the core fundamentals.

Positive Factors

Pipeline progress — pevifoscorvir Phase 2

Completion of the HBeAg- cohort and continued enrollment in the HBeAg+ cohort for the Phase 2 B-SUPREME study signal operational execution and de-risking over the next 2-6 months. Scheduled interim analyses provide durable, program-level readouts that can materially advance clinical validation and inform development strategy.

Pipeline diversification via partnership

Advancing ALG-170675 into IND-enabling studies in partnership spreads development risk, adds a distinct modality to the pipeline, and brings external resources/ expertise. That structural collaboration improves cadence to clinic and enlarges the company’s development portfolio beyond a single asset over a multi-month horizon.

Stronger financial governance

Promoting an experienced finance leader to Principal Accounting Officer strengthens accounting oversight and internal controls. Improved financial governance reduces reporting risk, supports clearer investor communications, and aids in executing financings or collaborations — a durable operational improvement for capital-intensive biotechs.

Negative Factors

No commercial revenue (2025)

Zero revenue in 2025 underscores that the company remains entirely pre-commercial and must rely on external funding or partnerships to sustain operations. Without product sales, the firm’s ability to self-fund trials is constrained, increasing the likelihood of dilution or deal-dependence over the coming months.

Persistent high cash burn

Consistently large negative operating and free cash flows indicate material runway pressure and an ongoing need for external capital. This structural cash burn limits strategic optionality, may force program prioritization or slower development pacing, and elevates financing and dilution risk for the next several quarters.

Eroding balance sheet / past negative equity

Material asset depletion and a period of negative stockholders’ equity signal weakened financial resilience. A thinner capital base reduces flexibility for partnerships or collateralized financing, tightens negotiating leverage, and heightens the consequences of further cash needs over the medium term.

Aligos Therapeutics Business Overview & Revenue Model

Company Description

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Aligos Therapeutics generates revenue through several key streams. Primarily, the company engages in research and development collaborations with larger pharmaceutical companies, which may include upfront payments, milestone payments based on the achievement of specific clinical or regulatory objectives, and royalties on future sales of products developed from these partnerships. Additionally, Aligos may receive funding from government grants or awards aimed at supporting innovative research in the biotech space. The company may also generate revenue through the licensing of its proprietary technologies or drug candidates to other firms in exchange for fees and royalties, enhancing its financial stability and growth prospects.

Aligos Therapeutics Financial Statement Overview

Summary

Income statement and cash flow are very weak: revenue fell to $0 in 2025 with persistent large operating losses and deeply negative operating/free cash flow, implying continued reliance on external funding. The balance sheet shows low debt but shrinking assets and a period of negative equity (2024), adding financing/dilution risk.

Income Statement

Operating performance remains very weak. Revenue has been volatile and ultimately collapsed to $0 in 2025 (annual), following $3.9M in 2024 and $15.5M in 2023, with a -100% revenue growth rate in 2025. Losses are persistent and sizable, with EBIT around -$88M to -$98M in recent years and net income negative every year shown (including -$24.2M in 2025 and -$131.2M in 2024). While the 2025 net loss narrowed materially versus 2024, the absence of revenue and continued heavy operating losses highlight a business still far from self-funding.

Balance Sheet

Leverage looks manageable on the years with positive equity, with debt-to-equity around ~0.06–0.12 from 2020–2023 and ~0.10 in 2025, supported by low absolute debt ($5.3M in 2025 vs. $88.5M total assets). However, equity and asset levels have eroded significantly over time (assets down from $265.3M in 2020 to $88.5M in 2025), and 2024 shows negative stockholders’ equity (-$29.0M), signaling past balance sheet stress. Returns on equity are consistently poor (negative in most years), reflecting ongoing losses and limiting the quality of the capital base.

Cash Flow

Cash burn remains the defining feature. Operating cash flow is deeply negative every year (about -$74M to -$116M), and free cash flow is similarly negative (about -$76M to -$117M), indicating the company is not close to funding operations internally. There is some improvement in 2025 versus 2024 (free cash flow improved modestly), but the overall trajectory still implies continued dependence on external financing and/or spending reductions to extend runway.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.19M	3.94M	15.53M	13.91M	4.36M
Gross Profit	1.26M	3.94M	15.53M	13.91M	4.36M
EBITDA	-87.06M	-86.53M	-85.06M	-93.91M	-124.54M
Net Income	-24.19M	-131.21M	-87.68M	-96.05M	-128.33M
Balance Sheet
Total Assets	88.53M	70.09M	151.53M	146.69M	235.37M
Cash, Cash Equivalents and Short-Term Investments	77.84M	56.94M	135.70M	125.83M	190.73M
Total Debt	5.25M	8.38M	11.14M	12.57M	14.46M
Total Liabilities	34.99M	99.07M	59.45M	42.79M	50.64M
Stockholders Equity	53.55M	-28.97M	92.08M	103.90M	184.73M
Cash Flow
Free Cash Flow	-82.94M	-80.87M	-79.02M	-80.33M	-116.55M
Operating Cash Flow	-82.50M	-80.74M	-79.00M	-79.39M	-115.66M
Investing Cash Flow	-37.83M	-18.28M	44.98M	-26.29M	3.02M
Financing Cash Flow	101.64M	355.00K	88.33M	164.00K	78.68M

Aligos Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 7.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Neutral. The current price of 7.57 is above the 20-day moving average (MA) of 7.04, below the 50-day MA of 7.75, and below the 200-day MA of 8.64, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 53.98 is Neutral, neither overbought nor oversold. The STOCH value of 71.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ALGS.

Aligos Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ACRV	49 Neutral	$51.12M	-0.96	-53.71%	―	―	21.17%
BRNS	46 Neutral	$25.69M	-0.43	-70.57%	―	-100.00%	-26.30%
CELU	44 Neutral	$35.18M	-0.59	763.31%	―	-15.81%	-113.06%
ALGS	42 Neutral	$46.84M	-1.22	-141.82%	―	-55.88%	6.14%

Aligos Therapeutics Corporate Events

Aligos Therapeutics Appoints New Principal Accounting Officer

On January 29, 2026, Aligos Therapeutics, Inc. appointed Nikhil Aneja as its Principal Accounting Officer, succeeding Lesley Ann Calhoun in that specific role while she continues as Executive Vice President, Chief Operating Officer and Chief Financial Officer. Aneja, 49, had been the company’s Vice President of Finance since February 2024 and brings prior senior finance and controller experience from diagnostic firm CareDx, Inc., as well as biopharmaceutical companies Blade Therapeutics, Inc. and Global Blood Therapeutics, Inc., underpinned by a commerce degree from the University of Delhi and Certified Public Accountant credentials, signaling a deepening of Aligos’s financial leadership bench and potential strengthening of its accounting oversight.

The most recent analyst rating on (ALGS) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.